Commentary

Is translational research compatible with preclinical publication strategies?

Stig Linder and Maria C Shoshan

Cancer Center Karolinska, Department of Oncology and Pathology, Karolinska Institute and Hospital, S-171 76 Stockholm, Sweden

author email corresponding author email

Radiation Oncology 2006, 1:4doi:10.1186/1748-717X-1-4

Published:	24 March 2006

Abstract

The term "translational research" is used to describe the transfer of basic biological knowledge into practical medicine, a process necessary for motivation of public spending. In the area of cancer therapeutics, it is becoming increasingly evident that results obtained in vitro and in animal models are difficult to translate into clinical medicine. We here argue that a number of factors contribute to making the translation process inefficient. These factors include the use of sensitive cell lines and fast growing experimental tumors as targets for novel therapies, and the use of unrealistic drug concentrations and radiation doses. We also argue that aggressive interpretation of data, successful in hypothesis-building biological research, does not form a solid base for development of clinically useful treatment modalities. We question whether "clean" results obtained in simplified models, expected for publication in high-impact journals, represent solid foundations for improved treatment of patients. Open-access journals such as Radiation Oncology have a large mission to fulfill by publishing relevant data to be used for making actual progress in translational cancer research.